TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03529331
Drug: Morphine Sulfate Immediate Release
Normalized name: morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mg Morphine Sulfate Immediate Release (MSIR) tablet 4 times a day for 5 days
Study: NCT03529331
Drug: Oxycodone/Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of Oxycodone/Acetaminophen (Percocet) tablet 4 times a day for 5 days
Study: NCT00955318
Drug: KW-6500
Normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of 1to 6 mg of KW-6500 for the OFF state
Study: NCT03148314
Drug: vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (800µgm.x 2 doses 3 hours).
Study: NCT03148314
Drug: buccal/sublingual misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 µgm.x4 hrs.x 6 doses
Study: NCT01332370
Drug: Rosiglitazone + Metformin
Normalized name: metformin / rosiglitazone
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: At least 180 days of continuous therapy with RSG+MET after the first Rx for RSG
Study: NCT01332370
Drug: Sitagliptin + Metformin
Normalized name: metformin / sitagliptin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: At least 180 days of continuous therapy with STG+MET after the first Rx for STG
Study: NCT03117920
Drug: Minnelide
Normalized name: Minnelide
DrugBank: Minnelide (DB17309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minnelide will be administered at the dose of 0.67 mg/m2 as a 30 min infusion intravenously daily on days 1-21 of each cycle followed by a 7 day rest period (days 22-28).
Study: NCT03894800
Drug: Methoxyflurane (M)
Normalized name: Methoxyflurane
DrugBank: Methoxyflurane (DB01028)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention inhalation of metoxyflurane 3 ml and NaCl i.v. will be administered.(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
Study: NCT03894800
Drug: NaCl (C)
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention NaCl i.v. and NaCl inhal will be used - placebo(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
Study: NCT01125930
Drug: Atralin gel
Normalized name: tretinoin Topical Gel [Atralin]
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Atralin gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use. This drug will be used for the duration of the study.
Study: NCT02049203
Drug: Ataciguat
Normalized name: Ataciguat
DrugBank: Ataciguat (DB12805)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04192682
Drug: Anlotinib Hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle, Combined With Sintilimab 200mg/time，21-day cycle。
Study: NCT02741284
Drug: Room air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02741284
Drug: 10L Oxygen by nonrebreather mask
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00732914
Drug: Sunitinib (Sutent)
Normalized name: sunitinib Oral Capsule [Sutent]
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib 50 mg once daily 4 weeks on, 2 weeks off, and after discontinuation (due to PD or toxicity), followed by sorafenib 400 mg BID
Study: NCT00732914
Drug: Sorafenib (Nexavar)
Normalized name: sorafenib Oral Tablet [Nexavar]
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib 400 mg BID, followed by Sunitinib 50 mg once daily 4 weeks on, 2 weeks off, and after discontinuation (due to PD or toxicity)
Study: NCT00152048
Drug: Eflornithine hydrochloride
Normalized name: Eflornithine Hydrochloride
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01451658
Drug: propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
Study: NCT03630666
Drug: IADT
Normalized name: Intranasal Amphetamine Dextroamphetamine Therapy
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will receive one injection of IADT at randomization
Study: NCT03202758
Drug: Durvalumab, Tremelimumab and ,FOLFOX
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Study will be performed in 2 step:~STEP 1 (phase Ib) will assess the safety of the combination of Durvalumab 750mg q2w + tremelimumab 75mg q4w + FOLFOX during the 2 first cycles of treatment (1 month)~STEP 2 (phase II) will assess the efficacy of the combination of Durvalumab 750mg q2w + tremelimumab 75mg q4w + FOLFOX
Study: NCT03942666
Drug: Treatment C
Normalized name: Acne Treatment Cream
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet of CHF 6532
Study: NCT03942666
Drug: Treatment D
Normalized name: Earwax Treatment Drops
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet of CHF 6532
Study: NCT03942666
Drug: Treatment E
Normalized name: Benzoyl Peroxide 10% Topical application Cream [ACNE TREATMENT EXTRA STRENGTH]
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo tablet of CHF 6532
Study: NCT03942666
Drug: Treatment F
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet of CHF 6532
Study: NCT01054599
Drug: Memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects in the treatment group will be placed on memantine. The dosage of memantine will begin at 5mg once per day (qday), and increase by 5mg every week. The titration will continue over a period of 3 weeks until a goal of 10mg bid is reached. The dosing will increase slowly, to minimize the risk of side effects. The subject will then remain on memantine at 10mg bid for 10 weeks, until the conclusion of the first phase of the study. At the conclusion of the first 13 weeks, subjects will discontinue the treatment (memantine or placebo) and enter the open label phase.
Study: NCT01054599
Drug: Memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open label: When the blinded phase is complete (Weeks 1-13), all subjects will receive open-label treatment with memantine (Weeks 14-26). The dosage of memantine will begin at 5mg once per day (qday), and increase by 5mg every week. The titration will continue over a period of 3 weeks until a goal of 10mg bid is reached. The dosing will increase slowly, to minimize the risk of side effects. The subject will then remain on memantine at 10mg bid for 10 weeks, until the conclusion of the study. At the conclusion of the study, subjects will discontinue the treatment.
Study: NCT01853306
Drug: Veliparib
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: veliparib
Study: NCT04521868
Drug: Sulforaphane
Normalized name: Sulforaphane
DrugBank: Sulforaphane (DB12422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.
Study: NCT01963611
Drug: Plovamer acetate 0.5 milligram (mg)
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plovamer acetate was administered at a dose of 0.5 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
Study: NCT01963611
Drug: Copaxone 20 mg
Normalized name: Copaxone 20 MG/ML Injectable Solution
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plovamer acetate was administered at a dose of 3 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
Study: NCT04272021
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard therapy for ADHD
Study: NCT01963611
Drug: Plovamer acetate 3 mg
Normalized name: Poloxamer
DrugBank: Poloxamer 407 (DB11252)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plovamer acetate was administered at a dose of 10 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
Study: NCT01963611
Drug: Plovamer acetate 10 mg
Normalized name: Poloxamer
DrugBank: Poloxamer 407 (DB11252)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plovamer acetate was administered as two subcutaneous injection of 10 mg weekly for 40 weeks up to a maximum of 14 months.
Study: NCT01963611
Drug: Plovamer acetate 20 mg
Normalized name: Poloxamer
DrugBank: Poloxamer 407 (DB11252)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copaxone was administered at a dose of 20 mg as subcutaneous injection once daily for 40 weeks up to a maximum of 14 months.
Study: NCT02253342
Drug: WCK-2349
Normalized name: Wck 771 free base
DrugBank: Levonadifloxacin (DB16219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive ten oral doses of 1000 mg WCK 2349 administered twice-daily starting on Day 1
Study: NCT01668043
Drug: Antibody UB-421
Normalized name: UB-612
DrugBank: UB-612 (DB16444)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UB-421 is administered by intravenous infusion
Study: NCT03118713
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral
Study: NCT03118713
Drug: ipragliflozin
Normalized name: ipragliflozin
DrugBank: Ipragliflozin (DB11698)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: oral
Study: NCT03118713
Drug: glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT01245790
Drug: fostamatinib
Normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral tablets, single dose
Study: NCT01813656
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole group,5mg/pill,10mg/day non-forced titration method,last 12weeks
Study: NCT00564525
Drug: Amitriptyline
Normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication taken for 4 weeks
Study: NCT00142298
Drug: Telbivudine (LdT)
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telbivudine was to be supplied as white to off-white, oval, bi-convex tablets for the 200 mg tablets and white to off-white ovaloid, slightly curved, beveled edges, film coated tablets for the 600 mg tablets. Study drug (600 mg) was to be self-administered by patients orally (p.o.) in a once daily regimen for 104 weeks; for study consistency, the daily dose had to be taken at the same time each day, with or without food.
Study: NCT03849313
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AVT02, a proposed similar biological product (biosimilar) of Humira which contains adalimumab . Adalimumab is a recombinant, fully human monoclonal immunoglobulin G1 (IgG1) antibody that binds specifically and with high affinity to the soluble and transmembrane forms of tumor necrosis factor (TNF)-α thereby inhibiting the binding of TNF-α with its receptor, and inhibiting TNF -α's biological function.~Tumor necrosis factor-α is a naturally occurring cytokine that is key to normal inflammatory and immune responses. Elevated levels of TNF-α are found in the synovial fluid of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis patients and psoriasis plaques and play an important role in both the pathologic inflammation and joint destruction that are hallmarks of these inflammatory diseases
Study: NCT01368523
Drug: nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03703713
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with Sodium chloride
Study: NCT01462214
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated with low-dose oral cyclophosphamide (8 different dose levels and schedules) in combination with fixed dose (10 mg) everolimus in patients with mRCC.
Study: NCT01339169
Drug: YF476
Normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg once daily for 12 weeks, with the option to increase to 75 mg or 100 mg once daily after 6 weeks, or decrease to 25 mg once daily, depending on response. After that, patients that have benefited from treatment may take 50 mg YF476 once daily for an additional up to 52 weeks.
Study: NCT04053790
Drug: lactobacillus LB
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of different doses of Lactobacillus LB according to the treatment groups described previously
Study: NCT00782067
Drug: Midostaurin (PKC412)
DrugBank: Midostaurin (DB06595)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Midostaurin was provided as 25 mg soft gelatin capsules for oral administration.
Study: NCT04130087
Drug: Selegiline Hydrochloride 10 MG
Normalized name: selegiline hydrochloride 10 MG
DrugBank: Selegiline (DB01037)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single 10mg tablet of Selegiline Hydrochloride
Study: NCT00649870
Drug: Valacyclovir Hydrochloride Tablets 1000 mg
Normalized name: Valacyclovir Hydrochloride
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000mg, single dose fed
Study: NCT00895232
Drug: Cohort I
Normalized name: IOBENGUANE I 123
DrugBank: Iobenguane (DB06704)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02841709
Drug: ACT-541468
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules for oral administration containing ACT-541468 at a strength of 5 mg, 10 mg or 25 mg
Study: NCT02333370
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg
Study: NCT02333370
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg
Study: NCT02333370
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg
Study: NCT02333370
Drug: goserelin
Normalized name: Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01802502
Drug: Rifampicin intravenous
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01802502
Drug: Oral rifampicin
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03940001
Drug: carboplatin/paclitaxel
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: carboplatin AUC 2/paclitaxel 50 mg/m2 weekly
Study: NCT00620490
Drug: ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine 0.5% 0.1 ml/kg per hour
Study: NCT00005520
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005520
Drug: Candesartan
Normalized name: Candesartan
DrugBank: Candesartan (DB13919)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01418157
Drug: Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 125 mg twice daily until 4380 meters altitude
Study: NCT02214407
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine (DAC) will be administered at 20 mg/m2 intravenously daily for 5 days every 28 days. Hydroxyurea may be added during the first 3 cycles if WBC counts \> 30 G/L, and mandatory if WBC \> 50 G/L. The daily dose will be adapted to maintain WBC below 15 to 20 G/L.~Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee.
Study: NCT02214407
Drug: HYDROXYUREA
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (HY) 1g/d once daily, with dose adjustments (up to 4g/d) to maintain a WBC count between 5 and 10 G/L. Allopurinol, 300mg/d started at the time of inclusion will be administered to all patients.~Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee.
Study: NCT00097435
Drug: Albuferon
Normalized name: Albuferon alpha
DrugBank: Albinterferon Alfa-2B (DB05396)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00097435
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00887653
Drug: raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This will be a single arm study where subjects will be given the option to switch from their current regimen to raltegravir at 400mg twice daily.
Study: NCT00739232
Drug: HSD-016
Normalized name: HSD-016
DrugBank: HSD-016 (DB12419)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02439190
Drug: BMS-986120
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02439190
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02439190
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03185988
Drug: chemotherapy in combination with trastuzumab for arm1
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Arm1: GI tumor beyond CRC, ESCC, BTC and GC\&GEJA Trastuzumab (Herceptin ®): 6 mg/kg every 3 weeks (8 mg/kg as loading dose at 1st administration), iv, d1.The first infusion is to be given over 90 minutes, and subsequent infusions are to be given over 30 minutes if the first infusion is well tolerated.Combined chemotherapy (by investigator's choice)
Study: NCT03185988
Drug: chemotherapy in combination with trastuzumab for arm2
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Arm2: esophageal squamous cell carcinoma (ESCC) Trastuzumab (Herceptin ®): the same as above Combined with Irinotecan: 120 mg/m2 IV, day 1 and day 8, every 3 weeks.
Study: NCT03185988
Drug: chemotherapy in combination with trastuzumab for arm3
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Arm 3: biliary tract cancer (BTC) Trastuzumab (Herceptin®): the same as above Combined chemotherapy (by investigator's choice) The combined chemotherapy of cohort 1 and 3 is Irinotecan: 120 mg/m2 IV, day 1and day 8, every 3 weeks.~OR 5-Fu: 720 mg/m2/day, continuous IV. Infusion over 5 days, every 3 weeks. OR Capecitabine(Xeloda®):1000 mg/m2 bid, d1-d14, every 3 weeks. The chemotherapy regimen is chosen at the Investigator's discretion and can be determined on an individual patient basis. Special cases should be discussed with the principal investigator.
Study: NCT03185988
Drug: chemotherapy in combination with trastuzumab for arm4
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab (Herceptin ®): same as above Combined with Irinotecan: 120 mg/m2 iv, day 1and day 8, every 3 weeks. OR Capecitabine(Xeloda®)1000 mg/m2 bid, d1-d14, every 3 weeks. OR Irinotecan: 120 mg/m2 iv, day 1and day 8 and Capecitabine(Xeloda®)1000 mg/m2 bid, d1-d14, every 3 weeks (by investigator's choice)
Study: NCT01578174
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine(Dexmedetomidine 2 mL and normal saline 98 mL mixed -\> 2㎍/mL) : the infusion of 0.2㎍/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4㎍/kg/hr after completion of procedure
Study: NCT03693300
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive 1500 mg Durvalumab monotherapy via IV infusion q4w for up to a maximum of 24 months with the last administration at Week 104.
Study: NCT03198650
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Acalabrutinib
Study: NCT03198650
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab
Study: NCT00000563
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01244659
Drug: Tacrolimus from EMS
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus initial dose of 0.2 mg/kg/day Myfortic®: 720 to 1440 mg/day Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.
Study: NCT01244659
Drug: Prograf
Normalized name: Prograf
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prograf initial dose of 0.2 mg/kg/day Myfortic®: 720 to 1440 mg/day Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.
Study: NCT02524379
Drug: Glyburide
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 day drug regimen beginning 8 hours after acute traumatic spinal cord injury.
Study: NCT01951950
Drug: Nicardipine
Normalized name: Nicardipine
DrugBank: Nicardipine (DB00622)
Approvals — FDA: yes, EMA: no, PMDA: no